Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888769 | 0.90 | S1PR1 (0.38) | ALDH1A1GAAS1PR1TSHRCTSS | |
| SCHEMBL4880805 | 0.90 | MAPT (0.42) | MAPTLMNAKMT2A | |
| SCHEMBL4888552 | 0.90 | CA2 (0.39) | S1PR1 | |
| SCHEMBL4886294 | 0.87 | NPC1 (0.45) | ALDH1A1GAATSHRMAPTHPGD | |
| SCHEMBL4890495 | 0.79 | CTSS (0.52) | ALDH1A1GAAS1PR1TSHRCTSS | |
| SCHEMBL14846086 | 0.76 | CYP1A2 (0.58) | ALDH1A1GAAS1PR1TSHRHPGD | |
| SCHEMBL4887744 | 0.75 | NOTUM (0.51) | ALDH1A1S1PR1TSHRMAPTLMNA | |
| SCHEMBL1610079 | 0.74 | TSHR (0.51) | ALDH1A1GAAS1PR1TSHRHPGD | |
| SCHEMBL14736015 | 0.72 | PDE10A (0.52) | ALDH1A1GAATSHRMAPTHPGD | |
| SCHEMBL6802722 | 0.72 | TACR1 (0.47) | TSHRCTSSCTSKMAPTHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | ALDH1A1 1003/4885GAA 1086/4885S1PR1 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.